GeoVax Labs, Inc. (GOVX) Earnings Call Transcripts

GeoVax Labs, Inc.'s Latest Earnings Call - May 28, 2026

In the Q1 FY2026 earnings call, GeoVax Labs, Inc. (GOVX:US) emphasized its strategic focus on developing the GEO-MVA vaccine, targeting Mpox and smallpox, with a pivotal Phase III trial set to begin in Q4 2026. Management highlighted an expedited regulatory pathway granted by the EMA, which allows them to bypass traditional Phase I and II trials, potentially accelerating their path to market. Revenue remains non-existent as the company is pre-revenue, but they raised over $4 million recently to support ongoing development efforts, indicating strong market interest driven by recent infectious disease outbreaks, particularly Ebola and Mpox.

Reported metrics

Guidance from management

GeoVax is focused on initiating the Phase III trial for GEO-MVA in Q4 2026 and expects to have results by mid-2027. They aim to secure additional funding to support this and future trials.

What management said

Durability of the immune responses. All we have to -- well, the durability -- the shelf life is typically 3 years and we'll be granted that if we meet the noninferiority. But we have gone back and tested and done tests in either animal models of monkeys where we went back 8 years after they have been vaccinated and they still maintain the immune response. So it's long-term durability with MVA. That has been recogniz...

Great question, one that I would not disclose even if we had -- first of all, we don't have that yet because we're not at that point to have a pricing dose, which is another reason why we wouldn't engage in contract discussions. That will be worked out between ourselves and our CDMO, OXB. We're working on that now and it's obviously tremendously assumption-driven. But what we will see as we move forward to the cell ...

What analysts pressed on

Analysts expressed concerns regarding the company's reliance on external funding and the risks associated with being a pre-revenue entity. There were also questions about the durability of immune responses and the anticipated pricing strategy for the GEO-MVA vaccine.

Main topics on the call

• Expedited Regulatory Pathway — GeoVax has received an expedited pathway from the EMA for its GEO-MVA vaccine, allowing it to skip Phase I and II trials. CEO David Dodd stated, "This is critically important because it moves us to the transformation of ...
• Upcoming Phase III Trial — The Phase III trial for GEO-MVA is scheduled to start in Q4 2026, with a target of 500 patients. Dodd mentioned, "We have already manufactured all the product. It's been packaged in the vials. It's ready to go."
• Market Opportunity for Mpox Vaccine — GeoVax estimates a $2 billion market for Mpox, with unmet demand for MVA vaccines exceeding $1.3 billion. Dodd highlighted, "We will be going after that gap," indicating a strong potential for revenue generation.
• Funding and Capital Raising — GeoVax raised over $4 million recently through equity sales and warrant exercises, which CEO Dodd described as a response to strong stock performance. He noted, "We continue to be raising money and adding to the balance ...

Read the full GeoVax Labs, Inc. transcript (May 28, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 19 GeoVax Labs, Inc. earnings call transcripts on record, spanning November 9, 2022 to May 28, 2026. Based on this history, GeoVax Labs, Inc. reports quarterly. The most recent call on file is dated May 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GOVX

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

19

First call

November 9, 2022

Most recent

May 28, 2026

Reporting cadence

quarterly